Roche and Hitachi High-Tech Renew 10-Year Partnership to Advance Diagnostic Innovation

Source: Overseas IVD Observer, Technology and Applications, etc.

This milestone cooperation not only continues the partnership between the two partiesLasting 46 yearsThe friendship and collaboration have injected new vitality and hope into the global diagnostic testing field.

Founded in Basel, Switzerland in 1896, Roche is one of the earliest industrial manufacturers of brand-name pharmaceuticals and has since grown into the world's largest biotechnology company and a global leader in in vitro diagnostics.

Hitachi High-Technologies Corporation, headquartered in Tokyo, engages in the manufacturing and sales of clinical analyzers, biotechnology products, radiotherapy systems, semiconductor manufacturing equipment, analytical instruments, and analytical devices. The company also provides high-value-added solutions in industrial fields such as mobility, connected vehicles, environmental energy, and more.

Since 1978, Roche and Hitachi High-Technologies have been working together to advance innovation and development in diagnostic technologies.

Over the past 46 years, Roche and Hitachi High-Technologies have jointly provided a wide range of innovative diagnostic solutions, helping patients worldwide achieve better treatment outcomes. Their collaboration goes beyond the technical level, integrating their long-accumulated expertise in diagnostic innovation, engineering, and manufacturing to create a powerful synergy. Currently,The Roche systems covered by this collaboration can process over 21 billion tests annually.，and with the signing of the new agreement, this figure is expected to continue rising.

The signing of this new agreement is not only an affirmation of the past cooperation achievements but also a firm commitment to a shared future vision. Roche and Hitachi High-Technologies stated that they will continue to explore new technologies, address the biggest challenges faced by laboratories worldwide, and jointly drive breakthroughs in the field of diagnostic testing.The two companies plan to launch new products in the coming months, including the cobas c 703 and cobas ISE neo analysis units., as part of the cobas pro integrated solution. These innovations aim to enhance laboratory testing capabilities, providing accurate and timely diagnoses for millions of people worldwide.

In addition,The two parties also plan to launch the cobas mass spectrometry solution by the end of this year., the integration of fully automated mass spectrometry into the daily operations of laboratories makes this gold-standard technology more accessible for various clinical applications worldwide. These innovations are not only transforming how diagnostics are delivered but also enhancing the sustainability and resilience of healthcare systems.

Palani Kumaresan, Head of Roche Diagnostics Solutions, stated: "I am delighted that through this new agreement, Roche and Hitachi High-Technologies can continue to push the boundaries of medical technology and transform patient care. Together, we have established an unparalleled installed base globally, with over 84,000 diagnostic platforms. This provides our customers with testing capabilities and scale, helping them better meet the needs of patients."

The success of this cooperation is not only due to the complementary technical advantages of both parties, but also because they are jointly committed to solving the major challenges faced by the healthcare field today and in the future.

In the next decade, Roche and Hitachi High-Technologies will continue to deepen their cooperation in diagnostic innovation, engineering, and manufacturing, jointly promoting advancements in the field of diagnostic testing. By introducing more innovative products and technologies, they aim to enhance laboratory testing capabilities and provide more accurate and timely diagnostic services for patients worldwide. Additionally, both parties will focus on improving sustainability within the diagnostics sector, addressing environmental issues such as plastic waste, and making greater contributions to global healthcare.

Roche will continue to leverage the advanced experimental equipment and data analysis technology of Hitachi High-Technologies to accelerate the drug development process and enhance the efficiency and quality of R&D. At the same time, both parties will jointly explore new models and pathways for drug development to meet the ever-changing demands of the pharmaceutical market. In terms of technology application, they will further strengthen cooperation in areas such as artificial intelligence, big data, and cloud computing. By jointly developing and applying new technologies, both parties will drive the digital transformation and intelligent upgrading of the pharmaceutical industry, improving the efficiency and quality of medical services. Additionally, the two sides will also explore new application scenarios and business models, injecting new momentum into the development of the pharmaceutical industry.

In summary, the renewal of the cooperation agreement between Roche and Hitachi High-Technologies not only affirms the achievements of their 46-year partnership but also reflects a promising outlook for collaboration in the next decade and beyond. Both parties will continue to move forward together, jointly driving breakthroughs and innovations in the field of diagnostic testing, and bringing better treatment outcomes and quality of life to patients worldwide.